SCHEMBL4060685

SCHEMBL4060685

FC(F)(F)c1ccc(Cc2nc3ncc(-c4ccco4)cc3[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.42
ADORA2A P29274 7/20 0.40
ADORA1 P30542 5/20 0.40
CACNA1H O95180 2/20 0.39
CACNA1G O43497 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRA6 Q16445 1/20 0.39
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
ADORA3 P0DMS8 4/20 0.38
PRMT5 O14744 1/20 0.36
ADORA2B P29275 1/20 0.36
PDE10A Q9Y233 1/20 0.36
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4056451 0.91 TRPV1 (0.44) KITADORA2AADORA1GABRA1GABRG2
SCHEMBL4059633 0.88 HPGD (0.38) ADORA2AADORA1CACNA1HCACNA1GPIK3R1
SCHEMBL4062213 0.88 ADORA2A (0.40) ADORA2AADORA1GABRA1GABRG2GABRB3
SCHEMBL4055088 0.87 PRNP (0.42) ADORA2AADORA1ADORA3PDE10ANOS3
SCHEMBL4054333 0.87 GAA (0.43) PDE10ATSHRNOS3NOS1NOS2
SCHEMBL4061234 0.86 NOS3 (0.45) ADORA2AADORA1PIK3R1PIK3CAADORA3
SCHEMBL4060932 0.86 MAPT (0.42) ADORA2AADORA1PIK3R1PIK3CAADORA3
SCHEMBL4051072 0.83 NOS3 (0.37) ADORA2AADORA1ADORA3PDE10ATSHR
SCHEMBL13608077 0.83 KIT (0.44) KITADORA2AADORA1CACNA1HCACNA1G
SCHEMBL4057348 0.83 NOS3 (0.48) ADORA2AADORA1ADORA3NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B KIT 493/4885ADORA2A 3069/4885ADORA1 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.